Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03562494 · ClinicalTrials.gov registry record · Phase 1
VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)
A Phase 1 study, sponsored by Neurocrine Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT03562494 is a Phase 1 study that has completed, run by Neurocrine Biosciences. The registered enrollment target is 14 participants.
The verdict
NCT03562494, a Phase 1 study, has completed, sponsored by Neurocrine Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The objective of this study is to assess the safety of VY-AADC02 in participants with Parkinson's disease (PD) with motor fluctuations.
Interventions
- BIOLOGICAL VY-AADC02
- OTHER Sham (Placebo) Surgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2018-10-17 |
| Est. Completion | 2024-10-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03562494
The ClinicalTrials.gov registry entry for NCT03562494 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neurocrine Biosciences, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which VY-AADC02 is the first listed.
NCT03562494 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03562494 about?
NCT03562494 is a clinical study titled "VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)". The objective of this study is to assess the safety of VY-AADC02 in participants with Parkinson's disease (PD) with motor fluctuations.
What is the current status of trial NCT03562494?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2018-10-17. Estimated completion is 2024-10-30.
What interventions are being tested in trial NCT03562494?
The interventions under investigation include: VY-AADC02 (BIOLOGICAL), Sham (Placebo) Surgery (OTHER).
Who is sponsoring clinical trial NCT03562494?
This trial is sponsored by Neurocrine Biosciences, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.